Long‐term assessment of recurrence of hepatocellular carcinoma in patients with chronic hepatitis C after viral cure by direct‐acting antivirals

DOI Web Site Web Site 参考文献23件 オープンアクセス
  • Eiichi Ogawa
    Department of General Internal Medicine Kyushu University Hospital Fukuoka Japan
  • Makoto Nakamuta
    Department of Gastroenterology, Kyushu Medical Center National Hospital Organization Fukuoka Japan
  • Norihiro Furusyo
    General Internal Medicine Taihaku Avenue Clinic Fukuoka Japan
  • Eiji Kajiwara
    Kajiwara Clinic Kitakyushu Japan
  • Kazufumi Dohmen
    Department of Internal Medicine Chihaya Hospital Fukuoka Japan
  • Akira Kawano
    Department of Medicine Kitakyushu Municipal Medical Center Kitakyushu Japan
  • Aritsune Ooho
    Department of Hepatology Steel Memorial Yawata Hospital Kitakyushu Japan
  • Koichi Azuma
    Department of Medicine Kyushu Central Hospital Fukuoka Japan
  • Kazuhiro Takahashi
    Department of Medicine Hamanomachi Hospital Fukuoka Japan
  • Takeaki Satoh
    Center for Liver Disease, Kokura Medical Center National Hospital Organization Kitakyushu Japan
  • Toshimasa Koyanagi
    Department of Medicine Fukuoka City Hospital Fukuoka Japan
  • Nobuyuki Yamashita
    The Center for Liver Disease Shin‐Kokura Hospital Kitakyushu Japan
  • Yasunori Ichiki
    Department of Internal Medicine JCHO Kyushu Hospital Kitakyushu Japan
  • Naoki Yamashita
    Department of Gastroenterology, Kyushu Medical Center National Hospital Organization Fukuoka Japan
  • Masami Kuniyoshi
    Department of Gastroenterology Kyushu Rosai Hospital Kitakyushu Japan
  • Kimihiko Yanagita
    Department of Internal Medicine Saiseikai Karatsu Hospital Karatsu Japan
  • Hiromasa Amagase
    Amagase Clinic Kitakyushu Japan
  • Chie Morita
    Department of Internal Medicine Kyushu Railway Memorial Hospital Kitakyushu Japan
  • Rie Sugimoto
    Department of Gastroenterology Kyushu Cancer Center Fukuoka Japan
  • Masaki Kato
    Department of Medicine and Bioregulatory Science, Graduate School of Medical Sciences Kyushu University Fukuoka Japan
  • Shinji Shimoda
    Department of Medicine and Biosystemic Science, Graduate School of Medical Sciences Kyushu University Fukuoka Japan
  • Hideyuki Nomura
    Department of Internal Medicine Haradoi Hospital Fukuoka Japan
  • Jun Hayashi
    Kyushu General Internal Medicine Center Haradoi Hospital Fukuoka Japan

抄録

<jats:title>Abstract</jats:title><jats:sec><jats:title>Background and Aim</jats:title><jats:p>Early hepatocellular carcinoma (HCC) recurrence is common, even after achieving hepatitis C virus (HCV) cure. This study was carried out to assess the long‐term trends and predictors of recurrence after HCV cure by direct‐acting antivirals (DAAs).</jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p>This retrospective, multicenter cohort study enrolled 365 consecutive patients with chronic hepatitis C who required HCC treatment following sustained viral response (SVR) by DAA administration. Patients with HCC recurrence before SVR were excluded. Late HCC recurrence and its predictors beyond the post‐treatment early phase (24 weeks after SVR) were evaluated.</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>The data of 326 patients were available for the final analysis. The median follow‐up duration from SVR determination was 2.7 years. Median age was 74, and 220 (67.5%) were 70 or over. The corresponding 5‐year cumulative HCC recurrence rates of previous curative and palliative treatment groups were 45.4% and 65.7%, respectively (log‐rank test: <jats:italic>P</jats:italic> < 0.001). Cox regression multivariable analysis revealed that cirrhosis (hazard ratio [HR] 1.85, <jats:italic>P</jats:italic> = 0.021), the number of HCC nodules (≥ 2) (HR 1.52, <jats:italic>P</jats:italic> = 0.031), and previous palliative HCC treatment (HR 1.71, <jats:italic>P</jats:italic> = 0.012) were independent predictors of late recurrence, in addition to the predictors of early recurrence; AFP > 7 ng/mL at 12 weeks after DAA administration, time from HCC complete response (CR) to DAA initiation (< 1 year), and the number of HCC treatments necessary to achieve CR (≥ 2).</jats:p></jats:sec><jats:sec><jats:title>Conclusions</jats:title><jats:p>The evaluation of fibrosis and characteristics of the previous HCC would allow for better HCC recurrence stratification, which would be helpful for developing long‐term surveillance strategies.</jats:p></jats:sec>

収録刊行物

参考文献 (23)*注記

もっと見る

関連プロジェクト

もっと見る

詳細情報 詳細情報について

問題の指摘

ページトップへ